Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Comput Biol Med. 2018 Dec 1;103:109-115. doi: 10.1016/j.compbiomed.2018.10.017. Epub 2018 Oct 16.
Metformin is the preferred first-line medication for management of type 2 diabetes and prediabetes. However, over a third of patients experience primary or secondary therapeutic failure. We developed machine learning models to predict which patients initially prescribed metformin will achieve and maintain control of their blood glucose after one year of therapy.
We performed a retrospective analysis of administrative claims data for 12,147 commercially-insured adults and Medicare Advantage beneficiaries with prediabetes or diabetes. Several machine learning models were trained using variables available at the time of metformin initiation to predict achievement and maintenance of hemoglobin A (HbA) < 7.0% after one year of therapy.
AUC performances based on five-fold cross-validation ranged from 0.58 to 0.75. The most influential variables driving the predictions were baseline HbA, starting metformin dosage, and presence of diabetes with complications.
Machine learning models can effectively predict primary or secondary metformin treatment failure within one year. This information can help identify effective individualized treatment strategies. Most of the implemented models outperformed traditional logistic regression, highlighting the potential for applying machine learning to problems in medicine.
二甲双胍是治疗 2 型糖尿病和糖尿病前期的首选一线药物。然而,超过三分之一的患者出现原发性或继发性治疗失败。我们开发了机器学习模型,以预测最初开处二甲双胍的患者在治疗一年后,其血糖控制将达到并维持。
我们对 12147 名有糖尿病前期或糖尿病的商业保险成年人和医疗保险优势受益人的行政索赔数据进行了回顾性分析。使用二甲双胍起始时可用的变量训练了几种机器学习模型,以预测治疗一年后血红蛋白 A(HbA)<7.0%的达标和维持情况。
基于五重交叉验证的 AUC 性能范围为 0.58 至 0.75。推动预测的最具影响力的变量是基线 HbA、起始二甲双胍剂量和伴发并发症的糖尿病。
机器学习模型可以有效地预测一年内二甲双胍的原发性或继发性治疗失败。该信息有助于识别有效的个体化治疗策略。大多数实施的模型优于传统的逻辑回归,突出了将机器学习应用于医学问题的潜力。